Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 260

1.

Anaesthesiology in China. Response to Br J Anaesth 2019; 123: 559-64.

Lambert DG.

Br J Anaesth. 2019 Nov;123(5):e521-e522. doi: 10.1016/j.bja.2019.09.007. Epub 2019 Sep 23. No abstract available.

PMID:
31558314
2.

A preclinical ultrasound method for the assessment of vascular disease progression in murine models.

Janus J, Kanber B, Mahbuba W, Beynon C, Ramnarine KV, Lambert DG, Samani NJ, Stringer EJ, Kelly ME.

Ultrasound. 2019 May;27(2):85-93. doi: 10.1177/1742271X18793919. Epub 2018 Aug 7.

PMID:
31037092
3.

Hot topics in opioid pharmacology: mixed and biased opioids.

Azzam AAH, McDonald J, Lambert DG.

Br J Anaesth. 2019 Jun;122(6):e136-e145. doi: 10.1016/j.bja.2019.03.006. Epub 2019 Apr 19. Review.

PMID:
31010646
4.

The good, the bad, and the ugly: the many faces of opioids.

Hemmings HC Jr, Lambert DG.

Br J Anaesth. 2019 Jun;122(6):705-707. doi: 10.1016/j.bja.2019.04.003. Epub 2019 Apr 18. No abstract available.

PMID:
31005244
5.

Mixed mu-nociceptin/orphanin FQ opioid receptor agonists and the search for the analgesic holy grail.

Lambert DG.

Br J Anaesth. 2019 Jun;122(6):e95-e97. doi: 10.1016/j.bja.2019.02.022. Epub 2019 Apr 5. No abstract available.

PMID:
30961914
6.

N/OFQ-NOP System in Peripheral and Central Immunomodulation.

Kadhim S, Bird MF, Lambert DG.

Handb Exp Pharmacol. 2019;254:297-311. doi: 10.1007/164_2018_203.

PMID:
30771012
7.

Perioperative medicine and UK plc.

Ackland GL, Galley HF, Shelley B, Lambert DG.

Br J Anaesth. 2019 Jan;122(1):3-7. doi: 10.1016/j.bja.2018.09.023. Epub 2018 Oct 26. No abstract available.

8.

Ketamine and depression.

Hirota K, Lambert DG.

Br J Anaesth. 2018 Dec;121(6):1198-1202. doi: 10.1016/j.bja.2018.08.020. Epub 2018 Oct 12. No abstract available.

9.

Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic.

Calo G, Lambert DG.

Br J Anaesth. 2018 Nov;121(5):1105-1114. doi: 10.1016/j.bja.2018.06.024. Epub 2018 Aug 22.

10.

Nociceptin/Orphanin FQ (N/OFQ) conjugated to ATTO594: a novel fluorescent probe for the N/OFQ (NOP) receptor.

Bird MF, Guerrini R, Willets JM, Thompson JP, Caló G, Lambert DG.

Br J Pharmacol. 2018 Dec;175(24):4496-4506. doi: 10.1111/bph.14504. Epub 2018 Nov 6.

11.

Opioids, gliosis and central immunomodulation.

Kadhim S, McDonald J, Lambert DG.

J Anesth. 2018 Oct;32(5):756-767. doi: 10.1007/s00540-018-2534-4. Epub 2018 Jul 27. Review.

PMID:
30054718
12.

In vitro and in vivo characterization of the bifunctional μ and δ opioid receptor ligand UFP-505.

Dietis N, Niwa H, Tose R, McDonald J, Ruggieri V, Filaferro M, Vitale G, Micheli L, Ghelardini C, Salvadori S, Calo G, Guerrini R, Rowbotham DJ, Lambert DG.

Br J Pharmacol. 2018 Jul;175(14):2881-2896. doi: 10.1111/bph.14199. Epub 2018 May 14.

13.

2017: A year of change for British Journal of Anaesthesia.

Lambert DG.

Br J Anaesth. 2018 Jan;120(1):1-2. doi: 10.1016/j.bja.2017.10.012. Epub 2017 Nov 23. No abstract available.

14.

Mitochondrial pharmacology turns its sights on the Ca2+ uniporter.

Storey NM, Lambert DG.

Cell Death Discov. 2017 Sep 25;3:17064. doi: 10.1038/cddiscovery.2017.64. eCollection 2017. No abstract available.

15.

In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403.

Ferrari F, Malfacini D, Journigan BV, Bird MF, Trapella C, Guerrini R, Lambert DG, Calo' G, Zaveri NT.

Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.333.

16.

Urotensin-II peptidomimetic incorporating a non-reducible 1,5-triazole disulfide bond reveals a pseudo-irreversible covalent binding mechanism to the urotensin G-protein coupled receptor.

Pacifico S, Kerckhoffs A, Fallow AJ, Foreman RE, Guerrini R, McDonald J, Lambert DG, Jamieson AG.

Org Biomol Chem. 2017 May 31;15(21):4704-4710. doi: 10.1039/c7ob00959c.

PMID:
28524918
17.

Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt1]N/OFQ(1-13).

Cerlesi MC, Ding H, Bird MF, Kiguchi N, Ferrari F, Malfacini D, Rizzi A, Ruzza C, Lambert DG, Ko MC, Calo G, Guerrini R.

Eur J Pharmacol. 2017 Jan 5;794:115-126. doi: 10.1016/j.ejphar.2016.11.026. Epub 2016 Nov 19.

18.

Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo).

Bird MF, Cerlesi MC, Brown M, Malfacini D, Vezzi V, Molinari P, Micheli L, Di Cesare Mannelli L, Ghelardini C, Guerrini R, Calò G, Lambert DG.

PLoS One. 2016 Jun 7;11(6):e0156897. doi: 10.1371/journal.pone.0156897. eCollection 2016.

19.

Effects of cannabinoid receptor activation by CP55,940 on normal bladder function and irritation-induced bladder overactivity in non-awake anaesthetised rats.

Bakali E, Mbaki Y, Lambert DG, Elliott RA, Mason R, Tincello DG.

Int Urogynecol J. 2016 Sep;27(9):1393-400. doi: 10.1007/s00192-016-2984-x. Epub 2016 Mar 4.

PMID:
26942594
20.

Evidence for nociceptin/orphanin FQ (NOP) but not µ (MOP), δ (DOP) or κ (KOP) opioid receptor mRNA in whole human blood.

Al-Hashimi M, McDonald J, Thompson JP, Lambert DG.

Br J Anaesth. 2016 Mar;116(3):423-9. doi: 10.1093/bja/aev540.

21.

Nociceptin/orphanin FQ (N/OFQ) modulates immunopathology and airway hyperresponsiveness representing a novel target for the treatment of asthma.

Singh SR, Sullo N, Matteis M, Spaziano G, McDonald J, Saunders R, Woodman L, Urbanek K, De Angelis A, De Palma R, Berair R, Pancholi M, Mistry V, Rossi F, Guerrini R, Calò G, D'Agostino B, Brightling CE, Lambert DG.

Br J Pharmacol. 2016 Apr;173(8):1286-301. doi: 10.1111/bph.13416. Epub 2016 Mar 6.

22.

Opioids and neovascularization; pro or anti?

Mahbuba W, Lambert DG.

Br J Anaesth. 2015 Dec;115(6):821-4. doi: 10.1093/bja/aev357. Epub 2015 Nov 3. No abstract available.

23.

Cannabinoid receptor expression in the bladder is altered in detrusor overactivity.

Bakali E, McDonald J, Elliott RA, Lambert DG, Tincello DG.

Int Urogynecol J. 2016 Jan;27(1):129-39. doi: 10.1007/s00192-015-2802-x. Epub 2015 Jul 30.

PMID:
26224382
24.

Validation of endogenous control reference genes for normalizing gene expression studies in endometrial carcinoma.

Ayakannu T, Taylor AH, Willets JM, Brown L, Lambert DG, McDonald J, Davies Q, Moss EL, Konje JC.

Mol Hum Reprod. 2015 Sep;21(9):723-35. doi: 10.1093/molehr/gav033. Epub 2015 Jun 29.

PMID:
26124453
25.

Simultaneous targeting of multiple opioid receptor types.

Bird MF, Lambert DG.

Curr Opin Support Palliat Care. 2015 Jun;9(2):98-102. doi: 10.1097/SPC.0000000000000129. Review.

PMID:
25872121
26.

Structure activity studies of nociceptin/orphanin FQ(1-13)-NH2 derivatives modified in position 5.

Guerrini R, Marzola E, Trapella C, Pacifico S, Cerlesi MC, Malfacini D, Ferrari F, Bird MF, Lambert DG, Salvadori S, Calo G.

Bioorg Med Chem. 2015 Apr 1;23(7):1515-20. doi: 10.1016/j.bmc.2015.02.008. Epub 2015 Feb 12.

PMID:
25716007
27.

Properdin levels in human sepsis.

Stover CM, McDonald J, Byrne S, Lambert DG, Thompson JP.

Front Immunol. 2015 Feb 2;6:24. doi: 10.3389/fimmu.2015.00024. eCollection 2015.

28.

Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands.

Bird MF, Vardanyan RS, Hruby VJ, Calò G, Guerrini R, Salvadori S, Trapella C, McDonald J, Rowbotham DJ, Lambert DG.

Br J Anaesth. 2015 Apr;114(4):646-56. doi: 10.1093/bja/aeu454. Epub 2015 Feb 13.

29.

International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function.

Vaudry H, Leprince J, Chatenet D, Fournier A, Lambert DG, Le Mével JC, Ohlstein EH, Schwertani A, Tostivint H, Vaudry D.

Pharmacol Rev. 2015;67(1):214-58. doi: 10.1124/pr.114.009480. Review.

PMID:
25535277
30.

Cebranopadol: a first in-class example of a nociceptin/orphanin FQ receptor and opioid receptor agonist.

Lambert DG, Bird MF, Rowbotham DJ.

Br J Anaesth. 2015 Mar;114(3):364-6. doi: 10.1093/bja/aeu332. Epub 2014 Sep 23. No abstract available.

31.

Exploring LPS-induced sepsis in rats and mice as a model to study potential protective effects of the nociceptin/orphanin FQ system.

Thomas RC, Bath MF, Stover CM, Lambert DG, Thompson JP.

Peptides. 2014 Nov;61:56-60. doi: 10.1016/j.peptides.2014.08.009. Epub 2014 Aug 23.

PMID:
25161013
32.

Long-term activation of polymorph cannabinoid receptors does not affect receptor gene transcription.

Beishon L, McDonald J, Thompson JP, Lambert DG.

Br J Anaesth. 2014 Jul;113(1):197-8. doi: 10.1093/bja/aeu218. No abstract available.

33.

In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives.

Rizzi A, Malfacini D, Cerlesi MC, Ruzza C, Marzola E, Bird MF, Rowbotham DJ, Salvadori S, Guerrini R, Lambert DG, Calo G.

Br J Pharmacol. 2014 Sep;171(17):4138-53. doi: 10.1111/bph.12799.

34.

Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Schröder W, Lambert DG, Ko MC, Koch T.

Br J Pharmacol. 2014 Aug;171(16):3777-800. doi: 10.1111/bph.12744. Review.

35.

Nociceptin system as a target in sepsis?

Thomas R, Stover C, Lambert DG, Thompson JP.

J Anesth. 2014 Oct;28(5):759-67. doi: 10.1007/s00540-014-1818-6. Epub 2014 Apr 12. Review.

PMID:
24728719
36.

Human urothelial cell lines as potential models for studying cannabinoid and excitatory receptor interactions in the urinary bladder.

Bakali E, Elliott RA, Taylor AH, Lambert DG, Willets JM, Tincello DG.

Naunyn Schmiedebergs Arch Pharmacol. 2014 Jun;387(6):581-9. doi: 10.1007/s00210-014-0973-5. Epub 2014 Mar 21.

PMID:
24652077
37.

Radioimmunoassay, enzyme and non-enzyme-based immunoassays.

Grange RD, Thompson JP, Lambert DG.

Br J Anaesth. 2014 Feb;112(2):213-6. doi: 10.1093/bja/aet293. Review. No abstract available.

38.

The Nociceptin/Orphanin FQ system is modulated in patients admitted to ICU with sepsis and after cardiopulmonary bypass.

Thompson JP, Serrano-Gomez A, McDonald J, Ladak N, Bowrey S, Lambert DG.

PLoS One. 2013 Oct 4;8(10):e76682. doi: 10.1371/journal.pone.0076682. eCollection 2013.

39.

The nociceptin/orphanin FQ receptor antagonist UFP-101 reduces microvascular inflammation to lipopolysaccharide in vivo.

Brookes ZL, Stedman EN, Brown NJ, Hebbes CP, Guerrini R, Calo G, Reilly CS, Lambert DG.

PLoS One. 2013 Sep 23;8(9):e74943. doi: 10.1371/journal.pone.0074943. eCollection 2013.

40.

Opioids and immune modulation: more questions than answers.

Al-Hashimi M, Scott SW, Thompson JP, Lambert DG.

Br J Anaesth. 2013 Jul;111(1):80-8. doi: 10.1093/bja/aet153. Review.

41.

Can anesthetic techniques or drugs affect cancer recurrence in patients undergoing cancer surgery?

Niwa H, Rowbotham DJ, Lambert DG, Buggy DJ.

J Anesth. 2013 Oct;27(5):731-41. doi: 10.1007/s00540-013-1615-7. Epub 2013 May 14. Review.

PMID:
23670802
42.

Immunity and early pregnancy events: are endocannabinoids the missing link?

Bambang KN, Lambert DG, Lam PM, Quenby S, Maccarrone M, Konje JC.

J Reprod Immunol. 2012 Dec;96(1-2):8-18. doi: 10.1016/j.jri.2012.10.003. Epub 2012 Nov 20. Review.

PMID:
23177537
43.

The effects of nociceptin peptide (N/OFQ)-receptor (NOP) system activation in the airways.

Singh SR, Sullo N, D'Agostino B, Brightling CE, Lambert DG.

Peptides. 2013 Jan;39:36-46. doi: 10.1016/j.peptides.2012.10.008. Epub 2012 Nov 1. Review.

PMID:
23123316
44.
45.

Measurement of [Ca²⁺]i in whole cell suspensions using Fura-2.

Patel A, Hirst RA, Harrison C, Hirota K, Lambert DG.

Methods Mol Biol. 2013;937:37-47.

PMID:
23007578
46.

[Dmt1]N/OFQ(1-13)-NH2: a potent nociceptin/orphanin FQ and opioid receptor universal agonist.

Molinari S, Camarda V, Rizzi A, Marzola G, Salvadori S, Marzola E, Molinari P, McDonald J, Ko MC, Lambert DG, Calo' G, Guerrini R.

Br J Pharmacol. 2013 Jan;168(1):151-62. doi: 10.1111/j.1476-5381.2012.02115.x.

47.

Evaluation of primary opioid receptor antibodies for use in western blotting.

Niwa H, Rowbotham DJ, Lambert DG.

Br J Anaesth. 2012 Mar;108(3):530-2. doi: 10.1093/bja/aes015. No abstract available.

48.

In vitro siRNA-mediated knockdown of the UT receptor: implications of density on the efficacy of a range of UT ligands.

Hunt BD, Ng LL, Lambert DG.

Naunyn Schmiedebergs Arch Pharmacol. 2012 Jun;385(6):651-6. doi: 10.1007/s00210-012-0728-0.

PMID:
22315015
49.

Pharmacological characterization of the bifunctional opioid ligand H-Dmt-Tic-Gly-NH-Bzl (UFP-505).

Dietis N, McDonald J, Molinari S, Calo G, Guerrini R, Rowbotham DJ, Lambert DG.

Br J Anaesth. 2012 Feb;108(2):262-70. doi: 10.1093/bja/aer377. Epub 2011 Dec 22.

50.

Direct effect of morphine on breast cancer cell function in vitro: role of the NET1 gene.

Ecimovic P, Murray D, Doran P, McDonald J, Lambert DG, Buggy DJ.

Br J Anaesth. 2011 Dec;107(6):916-23. doi: 10.1093/bja/aer259. Epub 2011 Aug 19.

Supplemental Content

Loading ...
Support Center